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Abstract: Alzheimer’s disease (AD) has been defined as a multi-factorial disorder resulting from
a complex array of networked cellular and molecular mechanisms. In particular, elevated levels
of Aβ protein and its aggregation products in the presence of metal ions proved to be highly
neurotoxic and therapeutic strategies aimed at preventing Aβ generation and oxidative stress may
represent an effective approach for AD treatment. A recent paradigm for the treatment of complex
diseases such as AD suggests the employment of multifunctional compounds, single chemical entities
capable of simultaneously modulating different targets involved in the pathology. In this paper, the
“pharmacophores combination” strategy was applied, connecting the main scaffold of the BACE-1
ligand 1 to that of the chalcone 2, as metal chelating pharmacophore, to obtain a small library of
compounds. Conjugate 5 emerged as the most interesting derivative, proving to inhibit BACE-1
with low-micromolar potency, and showing neuroprotective effects. In particular, 5 proved to be
able to protect from metal-associated oxidative stress by hampering intracellular Cu2+-induced ROS
formation without any direct neurotoxic effect.
Keywords: AD; BACE-1; benzophenone; chalcone; metal chelation; natural products; Reactive
oxygen species
1. Introduction
Alzheimer’s disease (AD), characterized by a progressive decline of cognitive and behavioral
functions, represents a considerable social, economic, and health burden due to its ever-increasing
incidence and prevalence. This is currently estimated to affect 24 million patients and this number is
predicted to increase fourfold by the year 2050 [1]. AD has been defined as a multi-factorial disorder,
being the result of a complex array of networked cellular and molecular mechanisms contributing to
neuronal dysfunction and degeneration. A recent paradigm to treat complex diseases, widely accepted
by the medicinal chemistry community, suggests the use of multifunctional compounds (MFCs), also
called multitarget drugs, which are single chemical entities capable of simultaneously modulating
different targets or pathways involved in the pathology [2,3].
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A number of key pathological changes can be observed in AD brain, namely amyloid-β (Aβ)
peptide extracellular deposits (amyloid neuritic plaques) and intracellular hyperphosphorylated
tau protein-based microtubule assemblies (neurofibrillary tangles). Additional features include
membrane-associated oxidative stress, neuroinflammation, biometal dyshomeostasis, mitochondrial
dysfunction and extensive loss of neurons and synapses. To date, the exact mechanisms leading to
these alterations still have to be fully uncovered.
A large body of evidence suggests that elevated levels of Aβ protein and its aggregation products,
such as pre-fibrillary small soluble Aβ oligomers and dimers, are highly toxic species. They positively
correlate with disease severity [4] due to their ability to trigger a cascade of neurobiological events,
namely oxidative damage, neuroinflammation and neurotoxicity, ultimately culminating in brain
atrophy, synaptic dysfunction and neuronal cell death [5]. Consequently, therapeutic strategies aimed
at preventing Aβ generation and toxicity may represent an effective approach for AD treatment.
Aβ protein is the results of amyloid precursor protein (APP) sequential cleavage by β- and γ-secretases.
In particular, β-secretase (also known as β-site APP cleaving enzyme-1, or BACE-1), the aspartyl
protease involved in the catalysis of the initial and rate-limiting step of APP processing, has been
validated to play a key role in regulating the formation of Aβ and related post-translational products.
Clinical trials outcomes demonstrated a direct correlation between BACE-1 inhibition and Aβ reduction.
Moreover, the elevated BACE-1 protein expression detected in AD patients brains [6] elected this
enzyme as attractive molecular target for disease-modifying drug discovery programs focused on the
development of “anti-amyloid” therapeutics. Substantial efforts have been put into the discovery of
small molecules as BACE-1 inhibitors in both academia and industry [7]. The various X-ray crystal
structures of BACE-1 alone and in complex with an inhibitor represent an essential source of structural
information for structure-based development of non-peptidic BACE-1 inhibitors with different core
templates [7–9].
Several metal ions, among which Cu(II), Fe(II) and Zn(II), largely found in AD plaques, are
known to be responsible for oxidative stress and neuronal cell death by promoting Aβ assembly and
enhancing reactive oxygen species (ROS) production [10]. Chemical entities endowed with metal
chelation properties proved to be able to hamper ROS generation and toxicity, together with metal-Aβ
interaction, and could represent a valuable approach for reducing neurotoxicity [11].
Natural products (NPs), small molecules synthesized by the plant kingdom, can be defined
“privileged structures” as they have undergone the natural selection process that allowed them to
achieve structural (chemical) features for optimal interactions with a wide range of biological targets.
Consequently, NPs possess different biological activities, responsible for a combination of therapeutic
effects. During the last decades, NPs represented an excellent source of lead compounds [12] and this
encouraged their employment as biologically pre-validated starting points for NPs-based approaches
of drug design and discovery [13]. In this context flavonoids, a class of polyphenolic NPs, showed
a wide therapeutic potential due to their ability to treat several human diseases including cancer,
inflammation and AD. They can be regarded as multitarget compounds, since various molecular
mechanisms are responsible for a single pharmacological effect. NPs proved to exert neuroprotective
activity by affecting different AD networked pathways and acting through different mechanisms
of actions, including suppression of neuroinflammatory responses and protection from neurotoxic
injuries, such as those derived from Aβ species, metal ions and oxidative stress [14]. Their metal
chelation ability was shown to depend on the presence of well-defined chelation sites in their structures,
such as a carbonyl function adjacent to a hydroxy group. The flavonoid-based metal chelates showed an
enhancement of several beneficial biological activities, among which the antioxidant effects, compared
to the corresponding simple flavonoids [15].
Design Strategy
The benzophenone core is known to be a privileged structure, suitable to be exploited to
provide effective ligands for different molecular targets involved in AD [16,17]. In an effort aimed at
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obtaining multipotent AD therapeutics, our in-house collection of naturally inspired small molecules
was screened against the BACE-1 enzyme, and some promising hit compounds were identified.
Among them, compounds 1 and 2 (Figure 1), bearing a benzophenone and a chalcone framework,
respectively, showed a promising BACE-1 inhibition (36% and 20%, respectively) when tested at
5 µM concentration. In a previous work, the benzophenone 1, bearing a N,N’-benzylmethylamine
moiety, was selected as the main scaffold to be optimized, allowing us to obtain a mutitarget AD-drug
candidate able to efficiently inhibit BACE-1 enzyme (low-micromolar potency) and to offer protection
against Aβ-induced neurotoxicity as well [18]. Moreover, computational studies showed that the
N,N’-benzylmethylamine function of 1 could appropriately interact with the catalytic dyad of the
enzyme. As for the second selected scaffold, chalcones (1,3-diarylpropen-1-ones) occupy a special
place as privileged structures among NPs. Peculiar chemical features of the hit 2 were an alkoxy side
chain and a hydroxyl group ortho to the carbonyl function (A-ring), while the B-ring was decorated
with a 3,4,5-trimethoxy substitution pattern.
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some AD targets such as the acetylcholinesterase enzyme [20]. Moreover, to assess the importance of 
the chalcone ortho-hydroxy-trans-α,β-unsaturated carbonyl framework for BACE-1 inhibition, this 
function was cyclized to a flavanone nucleus (to obtain compounds 6 and 7). Finally, applying a 
molecular simplification approach, the acetophenone-based derivative 3 was also included in the 
series. The new flavonoid-based conjugates were first tested on BACE-1 enzyme to assess their 
inhibitory potency. Then, the metal complexation potential of some selected candidates was also 
studied both in vitro and in solution. Finally, the ability to offer protection against metal induced 
oxidative stress was also investigated.  
Figure 1. Design strategy for the opti ization of the naturally inspired hits (1 and 2) to obtain
conjugates (4–7) as BACE-1 inhibitors. Inhibitory activities of 1 and 2 are reported.
A predominant approach for the design of multitarget agents is the “pharmacophores
combination” str tegy, that involves th arrangement of different ph rmacoph re units from selected
bioactive ligands to obtain analogues with an improved a d expanded biological profil [19].
Accordingly, in t is w rk, the main scaffold of the benzophenone 1 was combine with that of
the chalcone 2, which could also be considered a metal chelating pharmacophore that could allow to
widen the spectrum of biological activities of the obtained conjugate (analogue 4). To preliminarily
explore the SAR of this new hybrid, some structural modifications were performed, involving the
replacement of the electron rich 3,4,5-trimethoxy-phenyl ring with a rigid and planar naphthalene
moiety (5), since these groups proved to be valuable functions in the study of the chemical space of
some AD targets such as the acetylcholinesterase enzyme [20]. Moreover, to assess the importance
of the chalcone ortho-hydroxy-trans-α,β-unsaturated carbonyl f amework for BACE-1 inhibition, this
function was cyclized t a flavanone nucl us (to obtain compounds 6 a d 7). Finally, applying
a molecular simplification approach, the acetophenone-based derivative 3 was also included in the
series. The new flavonoid-based conjugates were first tested on BACE-1 enzyme to assess their
inhibitory potency. Then, the metal complexation potential of some selected candidates was also
studied both in vitro and in solution. Finally, the ability to offer protection against metal induced
oxidative stress was also investigated.
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2. Results
2.1. Chemistry
The synthetic route followed for the preparation of the chalcone-benzophenone conjugates
3–7 is depicted in Scheme 1. The hydroxylated benzophenone 8 was synthesized according to our
previously described procedure [17] and then subjected to Williamson reactions with the different
flavonoid-based derivatives 10–14, using a parallel synthesis apparatus, to give the final compounds
3–7. Intermediates 10–14 were obtained according to Scheme 2, in which 2,4-dihydroxyacetophenone
was alkylated with 1,2-dibromoethane in hot acetone and in the presence of K2CO3 to obtain key
intermediate 10, that underwent a Claisen-Schmidt condensation reaction with the selected aldehydes
and KOH, to produce the chalcone-based intermediates 11,12 in good yields (70%–90%); their
cyclization to the corresponding (˘) flavanones 13,14 was accomplished by treatment with sodium
acetate in refluxing ethanol. When 2,4-dihydroxyacetophenone was alkylated with 1-bromo-ethanol
under the abovementioned conditions, compound 9 was obtained, that underwent a Claisen-Schmidt
condensation with 3,4,5-trimethoxybenzaldehyde to give the final compound 2. Finally, compound 3
was obtained by Williamson reaction between 10 and 8.
Molecules 2016, 21, 643 4 of 16 
 
2. Results 
. . e istr  
 s t etic route followed for the prepar tion of the chalcone-b nzophenone conjugates 3–7 
is depicted in Schem  1. The hydroxylated benzophenone 8 was synthesized according t  r 
r i sl  scri  r c r  [ ]  t  s j ct  t  illi s  r cti s it  t  iff r t 
fl i - s  ri ti s , si   r ll l s t sis r t s, t  i  t  fi l c s 
. I ter e i tes  ere t i e  cc r i  t  c e e , i  ic  , - i r cet e e 
s l l t  it  , - i r t  i  t c t   i  t  r s c  f 2 3 t  t i   
i ter e i te 10, that underwent  Claisen-Schmidt condensation reaction with the selected 
ldehydes and KOH, to produce the ch lcone-based intermediates 11,12 in good yields (70%–90%); 
their cyclization to the c rresponding (±) flavanones 13,14 was accomplished by treatment with 
sodium acetate i  refluxing ethanol. When 2,4-dihydr xyacetophenone w s alkylated with 1-brom -
ethanol under the abovementioned conditions, compound 9 was obtained, that underwent a Claisen-
Schmidt condensation with 3,4,5-trimethoxybenzaldehyde to give the fi al compound 2. Finally, 
compound 3 was obtained by Williamson reaction between 10 and 8. 
 
Scheme 1. Synthesis of compounds 3–7. Reagents and Conditions: (i) K2CO3, acetone, reflux. 
 
Scheme 2. Synthesis of intermediates 10–14. Reagents and Conditions: (i) 1-Bromoethanol or  
1,2-dibromoethane, K2CO3, acetone, reflux; (ii) substituted benzaldehydes, KOH, EtOH, rt.; (iii) 
NaOAc, EtOH, 80 °C, reflux. 
Sche e 1. Synthesis of co pounds 3–7. Reagents and Conditions: (i) K2C 3, acetone, reflux.
2 1 h y
The yn h a e
e o ou
p ev ou y de bed p o edu e 17 and hen ub e ed o a on ea on h he d e en
avono d ba ed de va ve 10–14 u ng a pa a e yn he appa a u o g ve he na o pound
3–7 n d a 10–14 ob a n d a o d ng o S h 2 n h h 2 4 d hyd oxya oph non
a a ky a ed h 1 2 d b o oe hane n ho a e one and n he p e en e o o ob a n key
n d a a
a a
o
n o a o
n
Scheme 2. Synthesis of intermediates 10–14. Reagents and Conditions: (i) 1-Bromoethanol or
1,2-dibromoethane, K2CO3, acetone, reflux; (ii) substituted benzaldehydes, KOH, EtOH, rt.; (iii) NaOAc,
EtOH, 80 ˝C, reflux.
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2.2. Biological Evaluation
The new benzophenone-based hybrids 3–7 presented in this study were first evaluated for their
in vitro ability to inhibit the enzymatic activity of BACE-1, by means of a biochemical assay performed
using the fluorescence resonance energy transfer (FRET) methodology [21] and in comparison to
inhibitor IV [22] as reference compound (Table 1). For the most interesting compounds 3–5, endowed
with the orto-hydroxycarbonyl substitution pattern, the neuroprotective potential was determined as
lack of toxic effects on neuronal cell viability and as Cu(II) chelating activity (Table 2); moreover, their
direct interactions with Cu(II) ion were confirmed by a UV-vis spectrophotometric study.
Table 1. BACE-1 inhibitory potency of the new compounds 3–7 and reference compound (inhibitor IV).
Compound R hBACE-1 Inhibition IC50 (µM) a
3
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2.2.1. BACE-1 Inhibition
All the newly synthesized conjugates 3–7 showed good in vitro BACE-1 inhibitory potencies,
higher than the starting hits; data are reported in Table 1. More in detail, when the benzophenone
scaffold was linked to the flavonoid precursor acetophenone to give compound 3, an encouraging
result was obtained (IC50 = 3.18 µM). Indeed, the chalcone-benzophenone conjugates 4 and 5 also
showed good BACE-1 inhibition, as their potencies were maintained in the same low-micromolar
range as 3. In particular 4, bearing a 3,4,5-trimethoxyphenyl moiety, showed higher activity than the
starting chalcone-based derivative 2, and proved to be the most active of the series (IC50 = 1.06 µM),
slightly more potent than 5 carrying a 1-naphthyl function (IC50 = 4.02 µM). The corresponding
flavanone-benzophenone analogues 6 and 7, respectively, maintained the same trend of inhibition,
and again the 3,4,5-trimethoxyphenyl ring allowed compounds to achieve a more favorable enzyme
inhibition with respect to the naphthyl ring.
2.2.2. Neuroprotection
The neuroprotective potential was investigated for selected compounds 3–5 bearing the metal
chelating pharmacophore (ortho-hydroxycarbonylaryl), by evaluating: (a) the neurotoxic effects; (b) the
Cu (II) chelation ability; (c) the antioxidant properties.
Neurotoxicity
Cytotoxic effects in several in vitro or in vivo models have been reported for some chalcones [23].
Therefore, to discriminate the neurotoxic concentrations of the conjugates 3–5 we evaluated the
cell viability of human neuronal SH-SY5Y cells after 24 h treatment with these conjugate at
different concentrations (1.25–40 µM) using the MTT assay [24]. In our experimental conditions,
neurotoxic effects were recorded for acetophenone 3 (IC50 = 10.89 ˘ 1.63 µM) and chalcone 4
(IC50 = 23.66 ˘ 3.54 µM) but not for chalcone 5. Although, conjugate 4 showed some neurotoxic
effects, its low-micromolar BACE-1 IC50 value suggests a reasonably favorable selectivity index SI
(around 22). Thus, the presence of an α,β-unsatured carbonyl fragment seems to positively influence
the degree of neuronal toxicity, leading to molecules endowed with a favorable SI.
In Vitro Cu(II) Chelation
Bathocuproinedisulfonic acid disodium salt (BCS) [25] assay was employed to assess the Cu(II)
chelating ability of various concentration of conjugates 3–5 and the disodium salt of ethylene
diaminetetraacetic acid, (Na2EDTA, 5–20 µM), in the presence of a fixed 40 µM dose of CuSO4.
Data were expressed as chelating activity percentage (Table 2). The simplified analogue 3 showed
only a modest affinity for Cu(II) (5 µM, 0.00%; 10 µM, 3.49% ˘ 1.71%; 20 µM, 5.37% ˘ 0.16%), that
was improved by the presence in the molecule of the 3-aryl-propen-1-one framework, as in 4 (5 µM,
7.16% ˘ 0.24%; 10 µM, 10.77% ˘ 0.82%; 20 µM, 15.07% ˘ 1.32%) and 5 (5 µM, 9.48% ˘ 0.64%; 10 µM,
13.78% ˘ 1.74%; 20 µM, 19.73% ˘ 0.30%).
Total Antioxidant Activity
The total antioxidant capacity (TAC) of the selected conjugates 3–5, at various concentrations
(0.625–10 µM), was determined using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) inhibition assay [24,26].
In this context, no direct antioxidant effect was recorded (data not shown). Taking into account all
these preliminary results, conjugate 5, endowed with the best neuronal compatibility and Cu(II)
chelating ability, represents the most promising compound of the series, worth of further investigation
regarding its neuroprotective action, in particular the mechanism of action by which 5 may exert its
antioxidant activity.
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Inhibition of Cu(II)-Mediated ROS Formation
Our attention was then focused on the study of the intracellular antioxidant effect mediated by
Cu(II) chelation. Therefore, compound 5 was selected to be studied in SH-SH5Y cells for its ability to
counteract ROS formation elicited by Fenton reaction with CuSO4 (25 µM) and H2O2 (100 µM), and
using 21,71-dichlorodihydrofluorescein diacetate (H2DCF-DA) as the fluorescent probe [27]. As shown
in Figure 2, the conjugate 5 at 5 and 10 µM significantly decreased the ROS formation evoked by
H2O2/CuSO4, expressed as arbitrary fluorescence units (AUF). This finding suggests the ability of 5 to
stop the Fenton reaction through the Cu(II) chelation.
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fluorescence probe, as described in the Materials and Methods section. The arbitrary units of 
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ANOVA with Bonferroni’s Post Hoc Test). 
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that could somehow mimic this very complex situation, taking into account the solubility constrains 
as well. In alkaline media there is maximum deprotonation, but precipitation equilibria of Cu(II) 
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Figure 2. Effect of compound 5 on ROS formation elicited by H2O2/CuSO4 in SH-SY5Y cells. The cells
were treated with various concentrations of 5 and H2O2 (100 µM)/CuSO4 (25 µM) for 30 min. At the
end of the incubation, intracellular ROS formation was determined using a fluorescence probe, as
described in the Materials and Methods section. The arbitrary units of fluorescence (AUF) values are
shown as mean ˘ SD of at least three independent experiments (### P < 0.001 versus untreated cells,
*** P < 0.001 versus cells treated with H2O2/CuSO4, at ANOVA with Bonferroni’s Post Hoc Test).
2.3. Spectrophotometric Evaluation of Cu(II) Ion Complexation
Chalcone conjugates 4 and 5 were investigated to evaluate their ability to complex Cu(II) ions via
a UV-vis spectrophotometric study. The spectra, reported in Figure 3, showed that both compounds
were able to chelate the selected ion.
Flavonoids, in general, and ortho-hydroxychalcones in particular, thanks to their weak acidic
character, could be able to complex metal cations with more than one coordination site [11]. Therefore,
their affinity for the different metal ions strongly depends on the medium and pH. To experimentally
confirm via spectroscopic measurements the Cu(II) chelation effect observed in the physiological
environment for the selected chalcone conjugates 4 and 5, we had to choose a medium that could
somehow mimic this very complex situation, taking into account the solubility constrains as well.
In alkaline media there is maximum deprotonation, but precipitation equilibria of Cu(II) hydroxide
cannot be easily excluded and controlled.
Therefore, we decided to carry on the spectrophotometric measurements in a mixed solvent:
aqueous MOPS aqueous buffer 1 ˆ 10´2 M pH 7.4 /DMF in 1:4 ratio, respectively. Flavonoids bearing
the 4-carbonyl-5-hydroxyl chelation site have characteristic UV-vis spectra, characterized by a wide
and non-structured band centred around 370–380 nm, with a molar extinction coefficient of
50,000 cm´1¨M´1 that is attributed to HOMO-LUMO transition with a π-π* character.
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Figure 3. Titration curves of 4 (a) and 5 (b) (at 5 µM concentration) with increasing amounts of Cu(II)
in MOPS 10 mM pH 7.4/DMF (1:4). Inset: absorbance ratio at 382 nm versus Cu(II) equivalents.
The addition of increasing amounts of Cu(II) ions in solution caused a decrease of the maximum of
this band for both ligands, with a concomitant increase of the absorbance around 450 nm. These changes
are quite small, but in line with other similar systems already reported in the literature, and therefore
diagnostic for the copper complex formation [28].
Chalcones 4 and 5 underwent a UV-vis spectrophotometric study to evaluate their ability to
complex Cu(II) ions and the spectra were reported in Figures 3 and 4. It is important to underline that
chalcones, being multi-site metal cation binders, can generate complexes with different stoichiometries
and/or structures, thus it is difficult to discriminate among them only via spectrophotometric
measurements. Nevertheless, for both selected compounds during the titration procedure we observed
the formation of an isosbestic point (402 nm for 4 and 410 nm for 5, Figure 3a,b, respectively); this
feature is a clear indication that the complexation is taking place, even if it does not exclude multiple
equilibria involving different metal to ligand stoichiometries (as possibly suggested by the profile of
the inset of Figure 3).
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Figure 4. Absorption spectra of 4 4 ˆ 10´5 M in absence (solid line) and in presence (dotted line)
of 2.5 ˆ 10´5 M Cu(II) (a). Inset: spectral detail of the changing upon the addiction of the metal.
Absorption spectra of 5 4 ˆ 10´5 M in absence (solid line) and in presence (dotted line) of 2.5 ˆ 10´5 M
Cu(II) (b). Inset: spectral detail.
Furthermore, from the titration data an association constant was estimated that was of the order
of magnitude of 104 for a 1:1 complex stoichiometry. Undoubtedly, the complex cellular environment
could drastically influence the binding events, thus any structure prediction could be very difficult;
however, the study of the interactions performed in a simpler but similar surrounding could offer
very informative experimental evidences. In the light of these considerations, we have studied three
different concentrations of each ligand, reproducing the conditions of the biological study. As expected
from the titration results, for both 4 and 5 we observed the formation of the complexes as shown in
Figure 4 (data not shown for the other concentrations).
3. Discussion
Molecules able to modulate a single protein target prove to be ineffective for treatement of
multifactorial and complex disorders such as AD. Researchers are now turning to the design of
multitarget compounds, single chemical entities able to simultaneously modulate several molecular
targets or pathways involved in the disease, since these multipotent compounds could enable to
achieve a better efficacy profile compared to the single-target agents. Indeed BACE-1, catalyzing the
rate-limiting step in the generation of Aβ fragments, decreases the formation of Aβ. On the other
hand, Aβ is a metalloprotein that contains metal binding sites, and metals such as copper are present
at elevated concentrations in Aβ plaques and can promote the oligomerization of Aβ, increasing
its cytotoxicity. In this scenario, the “pharmacophores combination” design strategy was applied in
this study and two naturally inspired privileged structures, identified as weak BACE-1 inhibitors,
were connected. In particular, a benzophenone-based scaffold was conjugated to flavonoid-related
frameworks, namely chalcone and flavanone, as metal chelating pharmacophores. The small library
of hybrid molecules 3–7 turned out to inhibit BACE-1 enzyme with a low-micromolar potency
and the new compounds proved to be more active than the starting hit fragments. Moreover, the
chalcone-based analogues 4 and 5, endowed with an α,β-unsaturated carbonyl fragment, showed
an interesting biological profile in terms of ability to chelate Cu(II) ions, associated with a lack of
neurotoxic effects (favorable selectivity index).
Indeed redox active Cu(II) in complex with Aβ can generate H2O2, which may be converted
to hydroxyl radicals via Fenton reaction, resulting in oxidative cellular damage. Taking this into
account, 5 was also tested as an antioxidant and proved to be able to counteract the Cu(II)-dependent
ROS formation.
Finally, compound 5 proved to be a valuable multifunctional compound, able to protect from
common AD pathogenic events such as Aβ formation and Cu injury. It is thus characterized by
a low-micromolar inhibitory potency on BACE-1 enzyme, a good Cu (II) chelating ability (confirmed
also by UV-vis spectrophotometric studies) and a consequent efficacy to protect from Cu(II)-mediated
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toxicity. In summary, our initial design hypothesis was validated by the multipotent biological profile
of the benzophenone-chalcone conjugate 5 that represents a new promising lead compound, worth of
being further optimized and investigated in terms of structure-activity relationships (SAR). The results
of this study can be considered as the basis for the design of new small libraries of hybrids obtained by
conjugation of biologically relevant frameworks: the N,N’-benzylmethylamino-benzophenone scaffold
on one side and flavonoid-related frameworks on the other side.
4. Materials and Methods
4.1. General Information
Starting materials, unless otherwise specified, were high-purity commercial products.
Solvents were of analytical grade. Melting points were determined in open glass capillaries,
using a Büchi apparatus and are uncorrected. 1H-NMR and 13C-NMR spectra were recorded on
a Gemini spectrometer (400 MHz Varian, Palo Alto, CA, USA) and chemical shift are reported as
parts per million (ppm value) relative to the peak for tetramethylsilane (TMS) as internal standard.
Standard abbreviations indicating spin multiplicities are given as follows: s (singlet), d (doublet), t
(triplet), br (broad), q (quartet) or m (multiplet). Mass spectra were recorded on a ZQ 4000 apparatus
(Waters, Milford, MA, USA) operating in electrospray mode (ES). Chromatographic separations were
performed on silica gel columns by the flash method (Kieselgel 40, 0.040–0.063 mm, Merck, Darmstadt,
Germany). Reactions were followed by thin layer chromatography (TLC) on precoated silica gel plates
(Merck Silica Gel 60 F254) and then visualized with a UV lamp. The purity of the tested compounds
was determined by HPLC analysis, performed on a LC 1500 PU-1587 system (Jasco, Easton, MD,
USA); the column used was a Luna C18(2) 5 m 4.60 mm ˆ 150 mm (Phenomenex, Castel Maggiore
(BO), Italy); elution conditions: H3PO4 0.5%/ACN (75:25, v/v) the flow-rate was 1.2 mL/min and the
injection volume was 5 µL; peaks were detected at 254 nm and results were >98% purity. Compounds
were named relying on the naming algorithm provided in ChemDraw Professional 15.0, developed by
CambridgeSoft Corporation (Waltham, MA, USA).
4.2. Chemistry
4.2.1. General Procedure for the Synthesis of 3–7, 9, 10 by Williamson Reaction
To a room temperature solution of the phenol derivative (1.0 mmol) in acetone (10 mL) K2CO3
(1.1 mmol) was added, followed by the corresponding bromoalkyl derivative (1.0 mmol). The reaction
mixture was heated under reflux and the reaction progress was monitored by TLC. Upon reaction
completion, the mixture was hot filtered, and the solvent was evaporated under reduced pressure.
The resulting crude product was purified by column chromatography over a silica gel column using
a mixture of petroleum ether/ethyl acetate as the solvent system to give the desired pure products.
1-[2-Hydroxy-4-(2-hydroxyethoxy)phenyl]ethanone (9). Reaction of 2,4-dihydroxyacetophenone (5.0 mmol,
0.76 g) and 2-bromoethanol (5.5 mmol, 0.69 g, 0.39 mL) gave the crude product that was purified by flash
chromatography (petroleum ether/ethyl acetate 7/3).Yield = 85%, mp: 64–66 ˝C. 1H-NMR (CDCl3)
δ 2.56 (s, 3H, COCH3), 3.95–4.01 (m, 2H, CH2OH), 4.10–4.14 (m, 2H, OCH2), 6.40 (d, J = 1.8 Hz, 1H,
ArH-3), 6.50 (dd, J = 1.8 and 8.6 Hz, 1H, ArH-5), 7.64 (d, J = 8.6 Hz, 1H, ArH-6).
1-[2-Hydroxy-4-(2-bromoethoxy)phenyl]ethan-1-one (10). Reaction of 2,4-dihydroxyacetophenone
(5.0 mmol, 0.76 g) and 1,2-dibromoethane (5.0 mmol, 0.94 g, 0.45 mL), gave the crude product that
was purified by flash chromatography (petroleum ether/ethyl acetate 4:1).Yield = 85%, mp: 61–63 ˝C.
1H-NMR δ: 2.60 (s, 3H, COCH3), 3.83 (t, 2H, J = 6.00 Hz, CH2Br), 4.26 (t, 2H, J = 6.00 Hz, OCH2), 6.40
(d, J = 2.2 Hz, 1H, ArH-3) 6.48 (dd, J = 8.0 and 2.2 Hz, 1H, ArH-5), 7.65 (d, 1H, J = 9.20 Hz, ArH-6).
1-{4-[2-(4-4-Benzylmethylaminomethylbenzoylphenoxy)ethoxy]-2-hydroxyphenyl}ethan-1-one (3). Reaction of
benzophenone (Bp) 8 (1.0 mmol, 0.33 g) and 10 (1.1 mmol, 0.28 g) gave a crude product that was purified
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by flash chromatography (CH2Cl2/CH3OH 9.5:0.5) to give a semisolid compound, Yield = 51%, HCl;
mp: 264–268 ˝C. 1H-NMR (400 MHz, CDCl3) δ 2.33 (s, 3H, NCH3), 2.55 (s, 3H, COCH3), 3.56 (s, 2H,
NCH2), 3.59 (s, 2H, NCH2), 3.90–3.94 (m, 4H, OCH2CH2O), 6.48 (d, J = 2.2 Hz, 1H, Ch-Ar), 6.51
(dd, J = 8.0 and 2.2 Hz, 1H, Ch-Ar), 7.00 (d, 2H, J = 8.40 Hz, Bf-Ar), 7.26–7.46 (m, 5H, Bn-Ar), 7.49
(d, 2H, J = 8.60 Hz, Bf-Ar), 7.63 (d, 1H, J = 8.0 Hz, Ch-Ar), 7.75 (d, 2H, J = 8.60 Hz, Bf-Ar), 7.85 (d,
2H, J = 8.60 Hz, Bf-Ar). 13C-NMR (101 MHz, CDCl3): δ 26.64, 61.055, 61.62, 64.34, 64.66, 103.87, 106.98,
113.44, 126.90, 128.12, 128.52, 128.74, 128.86, 129.77, 130.41, 132.41, 136.91, 138.22, 143.69, 162.59, 165.11,
166.65, 197.56, 202.61. (ESI+) 510 m/z: [M + H]+.
E-1-{4-[2-(4-4-Benzylmethylaminomethylbenzoylphenoxy)ethoxy]-2-hydroxyphenyl}-3-(3,4,5-trimethoxy-
phenyl)prop-2-en-1-one (4). Reaction of Bp 8 (1.0 mmol, 0.33 g) and chalcone (Ch) 11 (1.1 mmol, 0.48 g)
gave a crude product that was purified by flash chromatography (CH2Cl2/CH3OH 9.25:0.75) to give
a semisolid compound. Yield = 65%, HCl; mp: 220–222 ˝C. 1H-NMR (400 MHz, CDCl3) δ 2.30 (s, 3H,
NCH3), 3.57 (s, 2H, NCH2), 3.59 (s, 2H, NCH2), 3.91 (s, 3H, OCH3), 3.94 (s, 6H, OCH3), 4.20–4.34
(m, 4H, OCH2CH2O), 6.50 (d, J = 2.2 Hz, 1H, Ch-Ar), 6.54 (dd, J = 8.0 and 2.2 Hz, 1H, Ch-Ar), 6.87
(s, 2H, Ch-Ar), 7.00 (d, 2H, J = 8.60 Hz, Bp-Ar), 7.16–7.36 (m, 5H, Bn-Ar), 7.26 (d, 1H, J = 15.60 Hz,
Ch-βCH=CH), 7.72 (d, 2H, J = 8.60 Hz, Ch-Ar), 7.78 (d, 1H, J = 8.60 Hz, Bp-Ar), 7.85 (d, 1H, J = 15.60 Hz,
Ch-αCH=CH), 7.88 (d, 2H, J = 8.60 Hz, Bp-Ar); 13C-NMR (101 MHz, CDCl3): δ 56.11, 60.85, 64.34,
64.66, 103.86, 106.93, 113.45, 118.74, 126.96, 128.17, 128.56, 128.71, 128.80, 129.70, 130.46, 132.45,
136.92, 138.24, 143.68, 145.32, 153.01, 153.22, 162.5, 165.11, 166.62, 197.58, 192.41. (ESI+) m/z: 687 [M + H]+.
E-1-{4-[2-(4-4-Benzylmethylaminomethylbenzoylphenoxy)ethoxy]-2-hydroxyphenyl}-3-(naphthalen-1-yl)-
prop-2-en-1-one (5). Reaction of Bp 8 (1.0 mmol, 0.33 g) and Ch 12 (1.1 mmol, 0.44 g) gave a crude
product that was purified by flash chromatography (CH2Cl2/CH3OH 9.25:0.75) to give a semisolid
compound. Yield = 51%, HCl: mp: 197–99 ˝C. 1H-NMR (400 MHz, CDCl3) δ 2.32 (s, 3H, NCH3), 3.59
(s, 2H, NCH2), 3.62 (s, 2H, NCH2), 4.30–4.40 (m, 4H, OCH2CH2O), 6.55 (d, J = 2.2 Hz, 1H, Ch-Ar), 6.58
(dd, J = 8.0 and 2.2 Hz, 1H, Ch-Ar), 7.02 (d, 2H, J = 8.60 Hz, Bf-Ar), 7.20–7.61 (m, 10H, Ar), 7.75 (d, 1H,
J = 16.4 Hz, β-CH=CH), 7.79–7.97(m, 8H, Ar), 8.03 (d, 1H, J = 8.0 Hz, Ch-Ar), 8.75 (d, 1H, J = 15.60 Hz,
αCH=CH); 13C NMR (101 MHz, CDCl3): δ 61.05, 61.62, 64.34, 64.66, 103.88, 106.96, 113.44, 121.33,
122.85, 126.14, 126.99, 128.19, 128.51, 128.76, 128.83, 129.72, 130.43, 132.48, 132.47, 133.54, 135.54, 136.94,
138.23, 143.63, 162.59, 165.11, 166.65, 197.50, 192.81. (ESI+) m/z: 648 [M + H]+.
7-{2-[4-(4-Benzylmethylaminomethylbenzoyl)phenoxy]ethoxy}-2-(3,4,5-trimethoxyphenyl)chroman-4-one (6).
Reaction of Bp 8 (1.0 mmol, 0.33 g) and flavone (Fl) 13 (1.1 mmol, 0.48 g) gave a crude product
that was purified by flash chromatography (CH2Cl2/CH3OH 9.5:0.5) to give a semisolid compound.
Yield = 59%, HCl: mp: 182–94 ˝C. 1H-NMR (400 MHz, CDCl3) δ 2.32 (s, 3H, NCH3), 2.87 (dd, 1H,
J = 16.5 and 2.8 Hz, H3a-Fl), 3.06 (dd, 1H, J = 16.5 and 13.1 Hz, H3b-Fl) 3.70 (s, 2H, NCH2), 3.74 (s, 2H,
NCH2), 3.87 (s, 3H, OCH3),3.90 (s, 6H, OCH3), 4.40–4.46 (m, 4H, OCH2CH2O), 5.37 (dd, 1H, J = 13.1
and 2.8 Hz, H2-Fl), 6.57 (d, J = 2.2 Hz, 1H, Fl-Ar), 6.70 (dd, J = 8.0 and 2.2 Hz, 1H, Fl-Ar), 6.75 (s, 2H,
Fl-Ar), 7.00 (d, 2H, J = 8.60 Hz, Bf-Ar), 7.26–7.36 (m, 5H, Bn-Ar), 7.78 (d, 1H, J = 8.60 Hz, Bf-Ar), 7.81
(d, 2H, J = 8.60 Hz,Bf-Ar), 7.86 (d, 2H, J = 8.60 Hz,Bf-Ar); 13C-NMR (101 MHz, CDCl3): δ 42.45, 56.10,
59.21, 61.05, 61.62, 64.34, 64.66, 83.44, 101.74, 103.86, 106.93, 113.46, 126.98, 128.12, 128.54, 128.76, 128.82,
129.78, 130.45, 132.43, 134.91, 136.92, 138.22, 143.67, 153.21, 138.74, 163.25, 165.11, 166.65, 197.51, 190.21.
MS (ESI+) m/z: 689 [M + H]+.
7-{2-[4-(4-(Benzylmethylaminomethylbenzoyl)phenoxy]ethoxy}-2-(naphthalen-1-yl)chroman-4-one (7).
Reaction of Bf 8 (1.0 mmol, 0.33 g) and Fl 13 (1.1 mmol, 0.44 g) gave a crude product that was purified
by flash chromatography (CH2Cl2/CH3OH 9.5:0.5) to give a semisolid compound. Yield = 45%, HCl:
mp: 172–95 ˝C. 1H-NMR (400 MHz, CDCl3) δ 2.22 (s, 3H, NCH3), 3.03 (dd, 1H, J = 16.5 and 2.8 Hz,
H3a-Fl), 3.26 (dd, 1H, J = 16.5 and 13.1 Hz, H3b-Fl) 3.54 (s, 2H, NCH2), 3.61 (s, 2H, NCH2), 4.36–4.48
(m, 4H, OCH2CH2O), 6.21 (dd, 1H, J = 13.1 and 2.8 Hz, H2-Fl), ), 6.57 (d, J = 2.2 Hz, 1H, Fl-Ar), 6.58
(dd, J = 8.0 and 2.2 Hz, 1H, Fl-Ar), 7.02 (d, 2H, J = 8.60 Hz, Bf-Ar), 7.20–7.61 (m, 10H, Ar), 7.79–7.97(m,
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8H, Ar), 8.05 (d, 1H, J = 8.0 Hz, Fl-Ar). 13C-NMR (101 MHz, CDCl3): δ 43.21, 61.05, 61.62, 64.34,
64.66, 80.80, 103.81, 106.93, 113.09, 113.43, 125.47, 126.41, 126.97, 128.17, 128.53, 128.78, 128.89, 129.79,
130.49, 132.45, 134.98, 136.31,136.95, 138.21, 136.88, 143.63, 162.57, 163.25, 165.11, 166.65, 197.57, 190.66.
MS (ESI+) m/z: 649 [M + H]+.
4.2.2. General Procedure for the Synthesis of Chalcones 2, 11, 12 by Claisen-Schmidt Reaction
To a solution of acetophenone (1.0 mmol) and substituted benzaldehyde (1.1 mmol) in ethanol
(10 mL), 50% KOH aqueous solution (3.0 mmol, 0.11 mL) was added dropwise. The reaction mixture
was stirred at r.t. overnight, then diluted with water and acidified with 6 N HCl. The solid formed was
collected by vacuum filtration and the crude residue was purified by flash column chromatography or
by crystallization from ethanol.
(E)-1-[2-Hydroxy-4-(2-hydroxyethoxyphenyl)]-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (2). Reaction of
9 (1.0 mmol, 0.19 g) and 3,4,5-trimethoxybenzaldehyde (1.1 mmol, 0.22 g) gave a crude that was
purified by flash chromatography (petroleum ether/ethyl acetate 7:3) to afford 2 as a yellowish solid.
Yield = 71%, mp: 186–188 ˝C. 1H-NMR (CDCl3) δ 3.91 (s, 3H, OCH3), 3.94 (s, 6H, OCH3), 4.00 (t,
J = 6.0 Hz, 2H, CH2OH), 4.13 (t, J = 6.0 Hz, 2H, OCH2), 6.47 (d, J = 2.2 Hz, 1H and H3), 6.52 (dd,
J = 2.2 and 8.2 Hz, 1H and H5), 6.87 (s, 2H, H2’ and H6’), 7.45 (d, J = 15.4 Hz, 1H, βCH=CH), 7.78 (d,
J = 15.4 Hz, 1H, αCH=CH), 7.84 (d, 1H, J = 8.6 Hz, H6). 13C-NMR (CDCl3) δ 56.23, 56.28, 60.33, 66.43,
79.51, 101.74, 105.81, 118.35, 118.44, 121.09, 121.26, 136.63, 136.66, 145.41, 147.48, 165.90, 166.64, 192.85.
MS (ESI+) m/z: 375 [M + H] +.
(E)-1-[4-(2-Bromoethoxy)-2-hydroxyphenyl]-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (11). Reaction of
10 (1.0 mmol, 0.26 g) and 3,4,5-trimethoxybenzaldehyde (1.1 mmol, 0.22 g) gave a crude that was
purified by crystallization from ethanol to afford 11 as a yellowish solid. Yield = 91%, mp: 170–172 ˝C.
1H-NMR δ 3.35 (t, 2H, J = 6.6, CH2-Br), 3.80 (s, 3H, OCH3), 3.84 (s, 6H, OCH3), 4.15 (t, 2H, J = 6.6 Hz,
OCH2), 6.45 (d, 1H, J = 2.2 Hz, H3), 6.54 (dd,1H, J = 2.2 and 8.2 Hz, H5), 6.88 (s, 2H, H2’ and H6’), 7.43
(d, 1H, J = 15.6 Hz, βCH=CH), 7.82 (d, J = 15.6 Hz, 1H, αCH=CH), 7.88 (d, 1H, J = 8.6 Hz, H6).
(E)-1-(4-(2-Bromoethoxy)-2-hydroxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one (12). Reaction of 10
(1.0 mmol, 0.26 g) and 1-naphthaldehyde(1.1 mmol, 0.16 g) gave a crude that was purified by
crystallization from ethanol to afford 12 as a yellowish solid. Yield 89%, mp: 140–142 ˝C. 1H-NMR δ
3.36 (t, 2H, J = 6.8, CH2-Br), 4.18 (t, 2H, J = 6.8 Hz, OCH2), 6.46 (d, 1H, J = 2.2 Hz, H3), 6.51 (dd, 1H,
J = 2.2 and 8.2 Hz, H5), 7.51–7.64 (m, 3H, Ar), 7.65 (d, 1H, J = 15.3 Hz, βCH=CH), 7.86–7.96 (m, 4H,
Ar), 7.87 (d, 1H, J = 8.6 Hz, H6), 8.25 (d, J = 15.6 Hz, 1H, αCH=CH).
4.2.3. General Procedure for the Synthesis of Flavanones 13, 14.
Chalcone (0.5 mmol) and sodium acetate (5.0 mmol) were dissolved in ethanol (10 mL) and the
solution was heated under reflux for 24 h. The reaction mixture was allowed to cool to r.t. and then
poured into ice/water (100 mL), and extracted with CH2Cl2 (3 ˆ 30 mL). The combined organic layers
were washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The crude
residue was purified by column chromatography using petroleum ether/ethyl acetate (7:3) as solvent
system, to afford the pure flavanone.
7-(2-Bromoethoxy)-2-(3,4,5-trimethoxyphenyl)chroman-4-one (13). From the reaction of 11 (0.5 mmol, 0.20 g)
and NaOAc (5.0 mmol, 0.04 g), 13 was obtained as pale yellow solid. Yield 48%, mp: 132–133 ˝C.
1H-NMR δ 2.89 (dd, 1H, J = 16.5 and 2.8 Hz, H3a), 3.11 (dd, 1H, J = 16.5 and 13.1 Hz, H3b), 3.35 (t,
2H, J = 6.6, CH2-Br), 4.26 (t, 2H, J = 6.6 Hz, OCH2),5.51 (dd, 1H, J = 13.1 and 2.8 Hz, H2), 6.43 (d, 1H,
J = 2.2 Hz, H3), 6.57 (dd,1H, J = 2.2 and 8.2 Hz, H5), 6.91 (s, 2H, H2’ and H6’), 7.8 (d, 1H, J = 8.6 Hz, H6).
7-(2-Bromoethoxy)-2-(naphthalen-1-yl)chroman-4-one (14). From the reaction of 12 (0.5 mmol, 0.20 g) and
NaOAc (5.0 mmol, 0.04 g), 14 was obtained as pale yellow solid. Yield 64%, mp: 115–117 ˝C. 1H-NMR δ
2.84 (dd, 1H, J = 16.5 and 2.8 Hz, H3a), 3.05 (dd, 1H, J = 16.5 and 13.1 Hz, H3b), 3.37 (t, 2H, J = 6.6,
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CH2-Br), 4.21 (t, 2H, J = 6.6 Hz, OCH2), 5.48 (dd, 1H, J = 13.1 and 2.8 Hz, H2), 6.53 (dd,1H, J = 2.2 and
8.2 Hz, H5), 7.54–7.68 (m, 3H, Ar), 7.85–8.01 (m, 4H, Ar), 7.88 (d, 1H, J = 8.6 Hz, H6).
4.3. BACE-1 Inhibition: FRET Inhibition Assay
Inhibition studies were performed using the following procedure: 5 µL of test compound (or
DMSO) were pre-incubated with 175 µL of enzyme (10.37 nM, final concentration) in 20 mM NaOAc
pH 4.5 containing CHAPS (0.1% w/v) for 1 h at r.t.; M-2420 (3 µM, final concentration) was then
added and left to react for 15 min. The fluorescence signal was read at λem = 405 nm (λexc = 320 nm).
DMSO concentration in the final mixture was maintained below 5% (v/v) to guarantee no significant
loss of enzyme activity.Fluorescence intensities with and without inhibitor were compared and the
percent inhibition due to the presence of test compounds was calculated. The background signal
was measured in control wells containing all the reagents, except theenzymeand subtracted. The %
inhibition due to the presence of increasing test compound concentration was calculated by the
following expression: 100 ´ (IFi/IFo ˆ 100) where IFi and IFo are the fluorescence intensities obtained
for the enzyme in the presence and in the absence of inhibitor, respectively. Inhibition curves
were obtained for each compound by plotting the % inhibition versus the logarithm of inhibitor
concentration in the assay sample. The linear regression parameters were determined and the IC50
extrapolated (GraphPad Prism 4.0, GraphPad Software Inc., San Diego, CA, USA).
4.4. Cu(II) Chelating Assay
The Cu(II) chelating activity of the compounds was determined using the bathocuproinedisulfonic
acid disodium salt (BCS) assay as previously described [25]. Briefly, 50 µL of a 0.25 mM CuSO4 solution
were mixed for 2 min with 50 µL of 5–20 µM compound solution in 100 µL of HEPES buffer (15 mM).
Hydroxylamine (1 mM) was added after 2 min in order to reduce non-chelated cupric ions into cuprous
ones. Finally, 50 µL of BCS (5 mM) or water (blank) was added and the absorbance at 490 nm was
measured by spectrophotometry using a multilabel plate reader (VICTOR™ X3, PerkinElmer, Waltham,
MA, USA) immediately and at 5 min. Na2EDTA (5–20 µM) was used as a positive control. The ability
of the test compounds to chelate cupric ions was calculated using the following equation: chelating
activity (%) = [1 ´ (Abs BCS + compound/Abs BCS) ˆ 100].
4.5. Cell Cultures
Human neuronal (SH-SY5Y) cells were routinely grown in Dulbecco’s modified Eagle’ Medium
(DMEM) supplemented with 10% fetal bovine serum, 2 mmol/L-glutamine, 50 U¨mL´1penicillin and
50 µg¨mL´1streptomycin at 37 ˝C in a humidified incubator with 5% CO2.
4.6. Determination of Neurotoxicity
To evaluate the neurotoxicity of compounds, the SH-SY5Y cells were seeded in 96-well plates at
2ˆ 104 cells/well, incubated for 24 h and subsequently treated with various concentrations of compounds
(1.25–40 µM) for 24 h at 37 ˝C in 5% CO2. The cell viability in terms of mitochondrial metabolic function
was evaluated by the reduction in 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) to formazan as previously described [27]. The quantity of formazan was directly proportional
to the number of viable cells. Briefly, the treatment medium was replaced with MTT (5 mg/mL) in
phosphate-buffered saline (PBS) for 2 h at 37 ˝C in 5% CO2. After washing with PBS, the formazan
crystals were dissolved with isopropanol. The amount of formazan was measured (570 nm, reference
filter 690 nm) using a multilabel plate reader (VICTOR™ X3, PerkinElmer, Waltham, MA, USA).
The neurotoxicity is expressed as concentration of compound resulting in 50% inhibition of cell viability.
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4.7. Determination of Antioxidant Activity
The total antioxidant activity of the compounds was determined using the stable DPPH
radical [24]. Briefly, 150 µL of 100 µM DPPH in ethanol was added to 50 µL of compound at different
concentrations (0.625–10 µM) in 96 well plate. The absorbance of the reaction mixture was measured at
490 nm on a multilabel plate reader (VICTOR™ X3) after 1 min, 15 min and 30 min. The values was
expressed as optical density of DPPH solution in absence or presence of compound.
The intracellular antioxidant activity of the compounds was evaluated in SH-SY5Y cells as
previously described with minor changes [27]. Briefly, the SH-SY5Y cells were seeded in 96-well plates
at 3 ˆ 104 cells/well and incubated for 24 h at 37 ˝C in 5% CO2. Subsequently cell culture medium
was removed and 100 µL of 21-71dichlorodihydrofluorescein diacetate, H2DCF-DA, (10 µg/mL) were
added to each wells. After 30 min of incubation at room temperature the H2DCF-DA solution was
replaced with a solution of compound [5 and 10 µM] and H2O2 (100 µM)/CuSO4 (25 µM). The ROS
formation was measured (excitation at 485 nm and emission at 535 nm) using a multilabel plate reader
(VICTOR™ X3). The values are expressed as arbitrary fluorescence units (AUF).
4.8. Spectrophotometricdetermination of Cu(II) Chelation
All reagents and solvents were used as received (from Aldrich, St. Louis, MO, USA) without
further purification: copper(II) sulphate hydrate (ě98%), 3-(N-Morpholino)propanesulfonic acid
(MOPS, ě99.5%), sodium hydroxide (ě98%), N,N-dimethylformamide (spectroscopic grade,
DMF). A Milli-Q system (Millipore, Billerica, MA, USA) was used for the purification of water
(resistivity ě18.2 MΩ). MOPS bufferstock solution were obtained by a dissolution in Milli-Q water of
3-(N-morpholino)propane sulphonic acid to a final concentration of 10´3 M. The pH was corrected
with a solution of sodium hydroxide 1 N to a value of pH 7.4. Absorption spectra were recorded on
a Perkin-Elmer Lambda 45 spectrophotometer at room temperature. Spectrophotometric titrations
were performed as follows: stock solutions of ligands (ca. 10´3 M) were prepared in DMF, diluted
down to the desired concentration, in the quartz cuvette, in MOPS buffer 10´3 M pH 7.4/DMF (1:4) to
a final volume of 2.5 mL and then titrated by adding increasing amounts of Cu(II) (3.04 ˆ 10´3 Min DMF).
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Abbreviations
The following abbreviations are used in this manuscript:
AD Alzheimer’s disease
Aβ amyloid β
APP amyloid β protein precursor
BACE-1 β-site APP cleaving enzyme-1
BBB blood brain barrier
Ch chalcone
CNS central nervous system
Fl flavanone




ROS reactive oxygen species
SPs senile plaques
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